Compare CTBI & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTBI | PHAT |
|---|---|---|
| Founded | 1903 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 894.0M |
| IPO Year | 1995 | 2019 |
| Metric | CTBI | PHAT |
|---|---|---|
| Price | $58.25 | $10.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $59.00 | $19.50 |
| AVG Volume (30 Days) | 52.9K | ★ 967.8K |
| Earning Date | 04-22-2026 | 05-28-2026 |
| Dividend Yield | ★ 3.59% | N/A |
| EPS Growth | 17.79 | ★ 42.72 |
| EPS | ★ 5.43 | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $14.02 | $91.62 |
| Revenue Next Year | $4.30 | $59.82 |
| P/E Ratio | $10.89 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $44.60 | $2.21 |
| 52 Week High | $65.79 | $18.31 |
| Indicator | CTBI | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 37.35 | 35.03 |
| Support Level | $53.77 | $7.82 |
| Resistance Level | $59.48 | $12.77 |
| Average True Range (ATR) | 1.91 | 0.80 |
| MACD | -0.42 | -0.03 |
| Stochastic Oscillator | 21.15 | 7.28 |
Community Trust Bancorp Inc is a bank holding company. The Bank owns all the capital stock of one commercial bank and one trust company, serving small and mid-sized communities in eastern, north-eastern, central, and south-central Kentucky, southern West Virginia, and north-eastern Tennessee. Through its subsidiaries, the Bank is engaged in commercial and personal banking and trust and wealth management activities, which include accepting time and demand deposits; making secured and unsecured loans to corporations, individuals, and others; providing cash management services to corporate and individual customers; issuing letters of credit; renting safe deposit boxes; and providing funds transfer services. The company operates in one reportable segment: community banking services.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.